Glibofit
Candidate of Science Bondarets I.A., Fedotkina N.A.
Municipal Institution
"Cherkasy Regional Hospital of Cherkasy Regional Council" Cherkasy, Ukraine
Summary:
The analysis of laboratory parameters of carbohydrate and lipid metabolism (fasting glucose, glycosylated hemoglobin, total cholesterol) was performed in patients with pre-diabetes and type 2 diabetes mellitus (70 people). Three clinical groups of patients (40 people with moderate type 2 diabetes mellitus, 10 people with mild type 2 diabetes mellitus and 20 people with pre-diabetes mellitus) were formed in accordance with the severity of carbohydrate metabolism. The analysis of the dynamics of certain carbohydrate and lipid metabolism parameters has shown that Glibofit had positive effect on patients with pre-diabetes and type 2 diabetes mellitus. The use of metformin at a daily dose of 1500-2000 mg in combination with Glibofit has caused a significant decrease of fasting glucose (by 17.9%), glycosylated hemoglobin (by 0.44%), and total cholesterol levels in patients of the first group. In patients of the second and third groups, the use of Glibofit has resulted in a significant decrease of fasting glycemia by 25.6% and 13% respectively. The glycosylated hemoglobin and total cholesterol parameters also tended to decrease. The obtained results confirm the rationality to use Glibofit in combination with hypoglycemic agents for the regulation of carbohydrate and lipid metabolism in patients with pre-diabetes and type 2 diabetes mellitus.
Keywords:
pre-diabetes, type 2 diabetes mellitus, Glibofit, fasting blood glucose, glycosylated hemoglobin, total cholesterol.